Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ZKK
|
|||
| Former ID |
DIB010311
|
|||
| Drug Name |
131I-81C6
|
|||
| Synonyms |
Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Terminated | [1] | |
| Company |
Duke University
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tenascin (TNC) | Target Info | . | [1], [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Focal adhesion | ||||
| ECM-receptor interaction | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Beta3 integrin cell surface interactions | ||||
| Alpha9 beta1 integrin signaling events | ||||
| Syndecan-4-mediated signaling events | ||||
| Reactome | Integrin cell surface interactions | |||
| Syndecan interactions | ||||
| ECM proteoglycans | ||||
| WikiPathways | TGF beta Signaling Pathway | |||
| Focal Adhesion | ||||
| Syndecan interactions | ||||
| Extracellular matrix organization | ||||
| Integrin cell surface interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502. | |||
| REF 2 | A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 April; 10(2): 182-189. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.